Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide
Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide
复制标题
DOI：
10.1086/518936
复制
发表时间：
2007-07-15
影响因子：
6.4
通讯作者：
Klimov, Alexander I.
中科院分区：
文献类型：
--
作者：
Deyde, Varough M.;Xu, Xiyan;Klimov, Alexander I.
我们以前的报告表明，在2001 - 2005年分离的甲型H3 N2流感病毒中，对金刚烷的耐药性惊人地增加。为了继续监测耐药性，我们对2005 - 2006年全球分离的甲型H3 N2和甲型H1N1流感病毒进行了全面分析。通过焦磷酸测序获得的结果表明，96.4%（n=761）在美国传播的A（H3 N2）病毒对金刚烷具有耐药性。一些亚洲国家的分离株的耐药性已达到100%。耐药性的出现和血凝素（HA）基因的进化途径之间的相关性分析表明，至少有2个单独的耐药性引入到循环人群中，产生了可识别的亚支。它还表明，2001年底亚洲可能出现了耐药性的A（H3 N2）病毒。在全世界分离的甲型H1N1流感病毒中，2005 - 2006年的耐药性达到15.5%;仅在美国，这一比例为4.0%。对HA和M基因的系统发育分析表明，甲型H1N1病毒获得耐药性可能与特定的基因组有关，而不是甲型H3 N2和甲型H1N1病毒之间重配的结果。研究结果强调了密切监测现有抗病毒药物耐药性的必要性以及对新疗法的需求。
Our previous reports demonstrated an alarming increase in resistance to adamantanes among influenza A( H3N2) viruses isolated in 2001 - 2005. To continue monitoring drug resistance, we conducted a comprehensive analysis of influenza A( H3N2) and A( H1N1) viruses isolated globally in 2005 - 2006. The results obtained by pyrosequencing indicate that 96.4% (n=761) of A( H3N2) viruses circulating in the United States were adamantane resistant. Drug resistance has reached 100% among isolates from some Asian countries. Analysis of correlation between the appearance of drug resistance and the evolutionary pathway of the hemagglutinin ( HA) gene suggests at least 2 separate introductions of resistance into circulating populations that gave rise to identifiable subclades. It also indicates that resistant A( H3N2) viruses may have emerged in Asia in late 2001. Among A( H1N1) viruses isolated worldwide, resistance reached 15.5% in 2005 - 2006; in the United States alone, it was 4.0%. Phylogenetic analysis of the HA and M genes indicates that the acquisition of resistance in A( H1N1) viruses can be linked to a specific genetic group and was not a result of reassortment between A( H3N2) and A( H1N1) viruses. The results of the study highlight the necessity of close monitoring of resistance to existing antivirals as wells as the need for new therapeutics.